NCT07354711RecruitingPhase 1/2
A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
A Phase I/II Study of 3H-10000 (an Anti-FGFR2b Antibody-Drug Conjugate) in Subjects With Unresectable or Metastatic Advanced Solid Tumors
Source: ClinicalTrials.gov · Last updated 21 Jan 2026
Brief summary (registry, in English)
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 170 (estimated)
- First submitted
- 13 Jan 2026
- Start date
- 4 Jan 2026
- Primary completion date
- Jan 2028
- Lead sponsor
- 3H Pharmaceuticals Co., Ltd.
- Diseases
- Lung cancer, Gastric and esophageal cancer
- NCT number
- NCT07354711
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 170
- From 4 Jan 2026 to the primary completion date, Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Having received treatment with other investigational drugs within 4 weeks prior to the first dose of the study drug.
- Any AEs induced by prior anti-tumor therapy having not resolved to Grade 1 or lower (except for alopecia or any other Grade 2 AEs assessed by the investigator as not being associated with any safety risk).
Other illness
- Meningeal diseases or carcinomatous meningitis.
- Any corneal or retinal disease/keratopathy assessed by the investigator as of clinical significance, including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, and keratoconjunctivitis.
Other
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage every two weeks or more frequently.
Who the study is looking for
- Subjects must be willing and able to sign the ICF and to adhere to the study visit schedule and other protocol requirements.
- Male or female subjects aged ≥18 years at the time of signing the ICF.
- According to RECIST v1.1, there is at least one measurable lesion.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 point.
- Life expectancy of ≥3 months.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Cancer Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.